|
|
|
|
| LEADER |
01621nam a2200349 u 4500 |
| 001 |
EB001872139 |
| 003 |
EBX01000000000000001035510 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 100 |
1 |
|
|a MacDonald, Erika
|
| 245 |
0 |
0 |
|a Benzydamine for the treatment of oropharyngeal mucositis from radiation therapy
|h Elektronische Ressource
|b a review of clinical effectiveness and guidelines
|c Erika MacDonald, Sarah Visintini
|
| 246 |
3 |
1 |
|a Benzydamine for the treatment of oropharyngeal mucositis
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2018, September 27, 2018
|
| 300 |
|
|
|a 1 PDF file (x pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Head and Neck Neoplasms / complications
|
| 653 |
|
|
|a Benzydamine / therapeutic use
|
| 653 |
|
|
|a Stomatitis / drug therapy
|
| 653 |
|
|
|a Radiation Injuries / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Benzydamine / standards
|
| 653 |
|
|
|a Mouthwashes / therapeutic use
|
| 700 |
1 |
|
|a Visintini, Sarah
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK538349
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective is of this report is to review the evidence and guidelines for use of benzydamine rinse for treatment of oropharyngeal mucositis secondary to radiation therapy
|